CN102947315A - 蛋白酪氨酸激酶活性抑制剂 - Google Patents

蛋白酪氨酸激酶活性抑制剂 Download PDF

Info

Publication number
CN102947315A
CN102947315A CN2011800297313A CN201180029731A CN102947315A CN 102947315 A CN102947315 A CN 102947315A CN 2011800297313 A CN2011800297313 A CN 2011800297313A CN 201180029731 A CN201180029731 A CN 201180029731A CN 102947315 A CN102947315 A CN 102947315A
Authority
CN
China
Prior art keywords
alkyl
heterocyclyl
substituted
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800297313A
Other languages
English (en)
Chinese (zh)
Inventor
S.雷佩尔
F.雷佩尔
S.W.克拉里奇
战莉洁
F.高德特
M.曼尼恩
N.萨托
Y.尤基
岸田雅司
A.韦斯伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methylgene Inc
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of CN102947315A publication Critical patent/CN102947315A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2011800297313A 2010-04-16 2011-04-08 蛋白酪氨酸激酶活性抑制剂 Pending CN102947315A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32480310P 2010-04-16 2010-04-16
US61/324,803 2010-04-16
PCT/CA2011/000394 WO2011127567A1 (en) 2010-04-16 2011-04-08 Inhibitors of protein tyrosine kinase activity

Publications (1)

Publication Number Publication Date
CN102947315A true CN102947315A (zh) 2013-02-27

Family

ID=44788641

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800297313A Pending CN102947315A (zh) 2010-04-16 2011-04-08 蛋白酪氨酸激酶活性抑制剂
CN201180029735.1A Expired - Fee Related CN103025740B (zh) 2010-04-16 2011-04-08 蛋白酪氨酸激酶活性的抑制剂及其治疗眼科疾病的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180029735.1A Expired - Fee Related CN103025740B (zh) 2010-04-16 2011-04-08 蛋白酪氨酸激酶活性的抑制剂及其治疗眼科疾病的用途

Country Status (19)

Country Link
US (3) US8455484B2 (enExample)
EP (2) EP2563795A4 (enExample)
JP (2) JP2013523846A (enExample)
KR (2) KR20130058006A (enExample)
CN (2) CN102947315A (enExample)
AR (2) AR080875A1 (enExample)
AU (2) AU2011241422B2 (enExample)
CA (2) CA2796008A1 (enExample)
CO (2) CO6640224A2 (enExample)
EA (2) EA201291055A1 (enExample)
MX (2) MX2012012032A (enExample)
MY (1) MY157319A (enExample)
NZ (2) NZ602954A (enExample)
PH (2) PH12012502070A1 (enExample)
SG (2) SG184882A1 (enExample)
TW (2) TW201204734A (enExample)
UA (1) UA108878C2 (enExample)
WO (2) WO2011127567A1 (enExample)
ZA (2) ZA201207482B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157737A1 (zh) * 2017-03-02 2018-09-07 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
KR20100137495A (ko) * 2008-03-05 2010-12-30 메틸진 인코포레이티드 단백질 티로신 키나아제 활성의 억제제
NZ602954A (en) * 2010-04-16 2014-11-28 Methylgene Inc Inhibitors of protein tyrosine kinase activity
US20130096135A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Selected Inhibitors of Protein Tyrosine Kinase Activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US20130090327A1 (en) * 2011-09-30 2013-04-11 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
EP2791108B1 (en) 2011-12-15 2016-07-27 Pfizer Limited Sulfonamide derivatives
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016183150A1 (en) * 2015-05-12 2016-11-17 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP6664170B2 (ja) * 2015-08-31 2020-03-13 広栄化学工業株式会社 アミノヒドロキシピリジン化合物の製造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004675A1 (en) * 2005-05-20 2007-01-04 Methylgene, Inc. Inhibitors of VEGF receptor and HGF receptor signaling
WO2009026717A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020619A1 (en) * 2003-07-24 2005-01-27 Patrick Betschmann Thienopyridine kinase inhibitors
CA2573538C (en) * 2004-07-30 2014-11-25 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CA2608726C (en) * 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
NZ602954A (en) * 2010-04-16 2014-11-28 Methylgene Inc Inhibitors of protein tyrosine kinase activity
WO2013044361A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004675A1 (en) * 2005-05-20 2007-01-04 Methylgene, Inc. Inhibitors of VEGF receptor and HGF receptor signaling
WO2009026717A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018157737A1 (zh) * 2017-03-02 2018-09-07 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
CN108530464A (zh) * 2017-03-02 2018-09-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂

Also Published As

Publication number Publication date
CN103025740A (zh) 2013-04-03
NZ602954A (en) 2014-11-28
TW201204734A (en) 2012-02-01
AU2011241420B2 (en) 2015-04-16
EP2563795A1 (en) 2013-03-06
NZ602948A (en) 2014-09-26
JP2013523846A (ja) 2013-06-17
MX2012012031A (es) 2012-12-17
AU2011241422B2 (en) 2015-05-07
CN103025740B (zh) 2015-07-01
US20140315801A1 (en) 2014-10-23
SG184882A1 (en) 2012-11-29
SG184883A1 (en) 2012-11-29
MY157319A (en) 2016-05-31
PH12012502070A1 (en) 2015-05-08
WO2011127567A1 (en) 2011-10-20
UA108878C2 (ru) 2015-06-25
PH12012502073A1 (en) 2013-02-11
EA201291055A1 (ru) 2013-09-30
MX2012012032A (es) 2012-12-17
US20110257175A1 (en) 2011-10-20
US8455484B2 (en) 2013-06-04
CO6640224A2 (es) 2013-03-22
ZA201207557B (en) 2013-06-26
EP2563794A1 (en) 2013-03-06
US8906852B2 (en) 2014-12-09
EP2563795A4 (en) 2013-10-23
EA201291052A1 (ru) 2013-04-30
AU2011241422A1 (en) 2012-11-01
ZA201207482B (en) 2013-09-25
JP2013525286A (ja) 2013-06-20
WO2011127565A1 (en) 2011-10-20
CA2796054A1 (en) 2011-10-20
CA2796008A1 (en) 2011-10-20
KR20130100234A (ko) 2013-09-10
KR20130058006A (ko) 2013-06-03
EP2563794A4 (en) 2013-12-04
AR080875A1 (es) 2012-05-16
US20110257100A1 (en) 2011-10-20
AR080871A1 (es) 2012-05-16
TW201204735A (en) 2012-02-01
CO6630193A2 (es) 2013-03-01

Similar Documents

Publication Publication Date Title
CN102947315A (zh) 蛋白酪氨酸激酶活性抑制剂
CN102015723B (zh) 蛋白酪氨酸激酶活性的抑制剂
CN105777776B (zh) 蛋白酪氨酸激酶活性的抑制剂
TWI537272B (zh) 製備抗病毒治療用的吡唑並［１，５-ａ］嘧啶類之方法
ES2924522T3 (es) Inhibidores heteroarilo de PAD4
CN109195965A (zh) Wdr5蛋白质-蛋白质结合的抑制剂
PT2729448E (pt) Compostos para o tratamento de vih
CN102015705A (zh) 稠合的杂环衍生物及其用途
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
AU2011241420A1 (en) Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
KR100877245B1 (ko) 인자 ｘａ 억제제로서의 피롤리딘 유도체
WO2013129435A1 (ja) 縮環チオフェン誘導体
WO2021218997A1 (zh) 取代的氮杂五元环类化合物及其在药物中的应用
HK1182379A (en) Inhibitors of protein tyrosine kinase activity
US20130096088A1 (en) Inhibitors of Protein Tyrosine Kinase Activity
WO2024149239A1 (zh) 杂芳环化合物及其制备方法和用途
TW201329084A (zh) 蛋白酪氨酸激酶活性選擇的抑制劑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1182379

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130227

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1182379

Country of ref document: HK